CYP and SXR gene polymorphisms influence in opposite ways acute rejection rate in pediatric patients with renal transplant

Stefano Turolo 1*, Alberto Edefonti 1, Luciana Ghio 1, Sara Testa 1, William Morello 1 and Giovanni Montini 1, 2

Abstract

Background: We evaluated the role of CYP3A5, ABCB1 and SXR gene polymorphisms in the occurrence of acute kidney rejection in a cohort of pediatric renal transplant recipients.

Methods: Forty-nine patients were genotyped for CYP3A5, ABCB1 and SXR polymorphisms and evaluated with tacrolimus trough levels in a retrospective monocenter study.

Results: Patients with the A allele of CYP3A5 treated with tacrolimus had a higher risk of acute rejection than those without the A allele, while patients carrying the homozygous GG variant for SXR A7635GG did not show any episode of acute rejection.

Conclusion: Genetic analysis of polymorphisms implicated in drug metabolism and tacrolimus trough levels may help to forecast the risk of acute rejection and individualize drug dosage in children undergoing renal transplantation.

Keywords: Kidney transplantation, Acute rejection, SXR, CYP, Tacrolimus, Pharmacogenomics

Background

Acute rejection occurs in up to 10–15% of patients during the first year following kidney transplantation [1], and is associated with long-term allograft dysfunction. The immune response directed against the graft is the result of either acute cellular rejection, due to a T-cell-dependent process, or acute humoral rejection, generated by B-cells [2–6]. Several factors influence the occurrence of acute rejection: recipient clinical and immunological characteristics (particularly HLA donor/recipient mismatch), donor clinical and biochemical data, and transplant-related factors [7]. Potent immunosuppressive agents have significantly increased the short- and long-term allograft and patient survival [8, 9], but inadequate doses of immunosuppressive drugs may be found in clinical practice, leading to clinical or subclinical reactivation of the immune system.

Tacrolimus is the main calcineurin inhibitor used in kidney transplantation in high-income countries [10]. It is metabolized by cytochrome P-450, encoded by the CYP genes cluster. It is well known that polymorphisms of the intracellular metabolizer enzyme CYP and the trans-membrane transport protein ABCB1 may influence enzymatic intracellular activity, modifying drugs metabolism [11–19]. Patients with the A allele on CYP3A5*3 need to double the dose of tacrolimus in order to reach therapeutic blood concentration [20]. Additionally, ABCB1 polymorphisms may affect, either positively or negatively, tacrolimus metabolism [21], even if to a lesser extent.

© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
extent. The expression of both CYP and ABCB1 genes is regulated by the intracellular receptor SXR [22, 23], which, after activation, makes up a heterodimer with various molecules to act as a transcriptional activator [23]. It has been reported that SXR A7635G, an intronic single nucleotide polymorphism (SNP), is able to increase tacrolimus clearance [24, 25]. On the other hand, studies in kidney transplant recipients showed no effect of this SNP on tacrolimus blood concentration [26, 27].

More recently, tacrolimus through levels were correlated with the risk of acute rejection during the first-year post transplantation [28]. However, a study of genes polymorphisms involved in the calcineurin pathway did not find any positive correlation between the main SNPs polymorphisms 500 µl of whole blood were collected during routine ambulatory control.

DNA extraction was performed by extractor Fuji QuickGene-810 (Fujifilm, Tokyo, Japan). PCR was carried out in 20 µl of a solution containing 2 µl of 10 x PCR Gold Buffer, 2 mM of MgCl₂, Applied Biosystem, Foster City, CA, USA), 80 µM each of dNTPs (Euroclone, Pero, Milan, Italy), 50 pmol each of primers for CYP3A and ABCB1 as previous described [32], 50 ng of genomic DNA and 0.6 U of AmpliTaq Gold (Applied Biosystem, Foster City, CA, USA). For the polymorphism of SXR A7635G and SXR−200 GAGAAG/− (rs3842689) we used the following primers: SXR A7635G forward 3’-TGG ATG CCA AGC TCA GTGG −5′; reverse 3’-CAG CAG CCA TCC CAT AAT CC −5′; for SXR rs3842689 we used the following primers pair: forward 3’-CTG ATG CTC TCT GGT CCT GC −5′, reverse 3’-TGC CTG CTA TAG CTG ATT CAT TG-5’ with a melt temperature of 60 °C for both polymorphisms.

The template was purified by liquid handling Biomek® 3000 (Beckman Coulter, CA, USA) using a magnetic particles system (Agenourt/Beckman Coulter, CA, USA). The single DNA strand was amplified by BigDye® 3.1 (Applied Biosystems, Foster City, CA USA) and then sequenced by a 3130xl Genetic Analyzer (Applied Biosystems/Hitachi, Foster City, CA USA).

Statistical analysis
Data were analyzed with Mann Whitney test for pharmacological data, and Fisher exact test for the acute rejection data, a p-value < of 0.05 was considered significant. All analyses were performed with SPSS software (IBM).

Results
Forty-nine pediatric patients who received a kidney transplant between January 2000 and December 2010, from either deceased (44) or living (5) donors, and who were treated with an immunosuppressive protocol including tacrolimus and with a complete set of tacrolimus trough blood levels and pharmacogenomic data were available for evaluation. Their demographic and clinical characteristics are shown in Table 1.
Eight patients had one episode of acute rejection during the first year post transplantation. Recipients’ HLA matches and mismatches are shown in Table 2. The majority of the patients (27/49) matched the donor HLA A, B and DR for at least one allele. Four or five mismatches were present in 22 patients. However, upon analyzing HLA matches/mismatches in the eight patients who had acute rejection episodes (Table 3), no correlation between the occurrence of acute rejection and HLA mismatches was apparent.

Acute rejection and SNPs
The number of acute rejection episodes in relation to the type of gene polymorphism (CYP3A5*3, CYP3A4B, ABCB1, SXR) is shown in Table 4. The twelve patients with A allele polymorphism for CYP3A5 had a significantly higher number of acute rejection episodes as compared to the 37 with GG polymorphism (p-value < 0.05 at Fisher exact test). The nine patients homozygous GG for SXR A7635G polymorphism did not show any acute rejection episode, in contrast with the patients who had rejection episodes pertaining to the cohort of 40 carriers of A allele (p-value < 0.05). No significant correlation was found between ABCB1 polymorphisms and rejection.

Drug trough level and genetic
Tacrolimus dose, blood trough levels and dose-normalized trough levels of the 49 patients from 6 to 360 days after transplantation are reported in Table 5 in relation to the different gene polymorphisms. Tacrolimus trough level (C0 normalized for dose/kg) of the 12 patients who were carriers of the A allele in CYP3A5*3 was significantly lower than that of the 37 who were not carriers (homozygous GG) throughout (p-value < 0.05 at Mann Whitney test for all considered time points). No differences were found in tacrolimus trough level of patients with all the other gene polymorphisms (data not shown).

Finally, considering the whole cohort of 49 patients (Table 6), no significant difference was present as regards tacrolimus trough levels between patients with acute rejection episodes and those without. Conversely, considering the eight patients with rejection episodes (Table 7), those with the A allele for CYP3A5*3 presented with a significantly lower tacrolimus trough level (p-value < 0.05 at Mann Whitney test) than those who were not carriers for A allele (homozygous GG). Moreover, the five patients with A allele for CYP3A5*3 who presented acute rejections episodes had a lower tacrolimus trough level in comparison to the seven who were carriers for allele A but did not show any acute rejection (p-value < 0.05 at Mann Whitney test).

Discussion
Several factors have been associated with the occurrence of acute rejection episodes during the first year after transplantation.

---

**Table 1** Demographic data of the pediatric renal transplant recipients

| Variable          | Value                  |
|-------------------|------------------------|
| Male/female       | 28/21 (n = 49)         |
| Age (Mean ± SD)   | 15.6 ± 6.1 (3 under 6 years of age) |
| Weight (Mean ± SD) Day 7: | 44.69 ± 17.87 kg |
|                   | Day 30: 44.86 ± 18.00 kg |
|                   | Day 90: 47.76 ± 18.7 kg |
|                   | Day 180: 49.31 ± 18.66 kg |
|                   | Day 360: 50.72 ± 18.09 kg |
| Ethnicity:        |                          |
| Caucasian:        | 46 (94.0%)             |
| Hispanic:         | 2 (4.0%)               |
| North Africa:     | 1 (2.0%)               |
| Primary renal disease |              |
| CAKUT             | 16 (32.6%)             |
| Glomerulonephritis| 12 (24.5%)             |
| Vasculitis        | 6 (12.2%)              |
| Tubulopathy       | 6 (12.2%)              |
| Other             | 9 (18.3%)              |

CAKUT = Congenital Abnormalities of the Kidneys and the Urinary Tract

**Table 2** Frequency of HLA allele mismatches in all 49 patients

| Number of HLA allele mismatches | Patients with HLA allele mismatches |
|---------------------------------|------------------------------------|
| 1                               | 4 (8.1%)                           |
| 2                               | 8 (16.3%)                          |
| 3                               | 15 (30.6%)                         |
| 4                               | 11 (22.4%)                         |
| 5                               | 11 (22.41%)                        |
| 6                               | 0                                  |

**Table 3** HLA hetero and homozygous match/homozygous mismatch in the 8 patients who had acute rejection (AR) episodes

| Patient | HLA A | HLA B | HLA DR | Match/mismatch |
|---------|-------|-------|--------|----------------|
| Patient 1 | Match | Match | Match | 3/0           |
| Patient 2 | Match | Match | Match | 3/0           |
| Patient 3 | Match | Match | Match | 3/0           |
| Patient 4 | Match | Mismatch | Mismatch | 1/2           |
| Patient 5 | Match | Match | Match | 3/0           |
| Patient 6 | Match | Match | Match | 3/0           |
| Patient 7 | Match | Mismatch | Match | 2/1           |
| Patient 8 | Match | Match | Mismatch | 2/1           |

Turolo et al. BMC Pediatrics (2020) 20:246
renal transplantation, namely the number of HLA mismatches, a low immunosuppressive drug blood concentration and, more recently, a series of gene polymorphisms [7, 28].

In our population, HLA mismatch did not seem to play a significant role in determining acute rejection rate (Table 3). Additionally, HLA mismatch had no significant role in the occurrence of acute rejection in a recent report by Parajuli et al., who analyzed 1102 kidney biopsies and did not find any correlation between the HLA mismatch and the risk of acute rejection [33].

The role of changes in drug metabolism, induced by polymorphisms of a number of genes, has been repeatedly underlined in the last two decades [11–19]. In particular, blood concentration of immunosuppressive drugs has a pivotal role in preventing acute rejection and allograft failure. Therapeutic tacrolimus blood concentration is particularly important during the first 3

| Table 4 | Number of acute rejection episodes in relation to the different gene polymorphisms |
|---------|----------------------------------------------------------------------------------|
| GENE    | polymorphism                      | N° of acute rejection episodes |
|---------|-----------------------------------|------------------------------|
| CYP3A5  | AG (n = 12) (24.4%)               | 5* (41.6%)                   |
|         | GG (n = 37) (75.5%)               | 3 (1.0%)                     |
| CYP3A4B | AA (n = 43) (87.7%)               | 7 (16.2%)                    |
|         | AG (n = 6) (12.2%)                | 1 (16.6%)                    |
| SXR A7635G | AA (n = 16) (32.6%)          | 2 (12.5%)                    |
|         | AG (n = 24) (48.9%)               | 6 (25.0%)                    |
|         | GG (n = 9) (18.3%)                | 0* (0.0%)                    |
| SXR RS rs3842689 | In/In (n = 19) (38.7%) | 3 (12.9%)                  |
|         | In/del (n = 22) (44.8%)           | 4 (18.1%)                    |
|         | Del/del (n = 8) (16.32%)          | 1 (12.5%)                    |
| ABCB1 C1236T | CC (n = 18) (36.7%)         | 3 (16.6%)                    |
|         | CT (n = 19) (38.7%)               | 2 (10.5%)                    |
|         | TT (n = 12) (24.4%)               | 3 (0.25%)                    |
| ABCB1 G2677T/A | GG (n = 16) (32.6%)       | 2 (12.5%)                   |
|         | GT/A (n = 26) (53.0%)             | 5 (19.2%)                    |
|         | TT (n = 7) (14.2%)                | 1 (14.2%)                    |
| ABCB1 C3435T | CC (n = 15) (30.6%)             | 4 (26.6%)                   |
|         | CT (n = 24) (48.9%)               | 2 (8.3%)                     |
|         | TT (n = 10) (20.4%)               | 2 (20.0%)                    |

* p-value < 0.05 at Fisher exact test

| Table 5 | Tacrolimus pharmacokinetic data in relation to CYP3A5 and SXR A7635G gene polymorphisms in the 49 patients of the study |
|---------|-------------------------------------------------------------------------------------------------------------|
| Days    | CYP3A5*3 AA/AG (12 patients) | CYP3A5*3 GG (37 patients) | SXR A7635G AA (16 patients) | SXR A7635G AG (24 patients) | SXR A7635G GG (9 patients) |
|---------|----------------------------------------------------------------------|-----------------|-----------------|-----------------|-----------------|
| Dose/kg (mg/kg) | day 7      0.17 ± 0.10  0.15 ± 0.06  0.18 ± 0.10  0.14 ± 0.04  0.16 ± 0.08  |
|            | day 30     0.18 ± 0.10  0.13 ± 0.06  0.17 ± 0.11  0.14 ± 0.05  0.14 ± 0.07  |
|            | day 90     0.15 ± 0.09  0.11 ± 0.06  0.14 ± 0.10  0.10 ± 0.05  0.12 ± 0.07  |
|            | day 180    0.13 ± 0.08  0.09 ± 0.06  0.11 ± 0.09  0.08 ± 0.04  0.11 ± 0.07  |
|            | day 360    0.11 ± 0.08  0.07 ± 0.05  0.10 ± 0.08  0.07 ± 0.03  0.08 ± 0.07  |
| CO/(dose/kg) (ng/ml)/(mg/kg) | day 7  67.52 ± 48.67*  80.67 ± 58.46  95.47 ± 82.73  64.13 ± 24.06  79.11 ± 53.07  |
|            | day 30     73.83 ± 105.88* 111.45 ± 70.37 103.21 ± 87.98 97.40 ± 60.02 111.86 ± 118.66  |
|            | day 90     91.59 ± 139.61* 114.52 ± 68.18 103.33 ± 76.67 108.79 ± 64.90 119.26 ± 157.82  |
|            | day 180    70.48 ± 137.70* 137.70 ± 103.44 121.30 ± 101.09 127.20 ± 106.22 104.06 ± 70.10  |
|            | day 360    72.56 ± 182.92* 182.92 ± 199.75 192.34 ± 283.35 142.93 ± 103.30 121.24 ± 78.97  |

Data are expressed as mean ± S.D. * p-value < 0.05 at Mann Whitney test
months after transplantation [34] and a wide therapeutic window, from 5 to 9.5 ng/ml, is warranted during the first-year post transplantation [35]. To elucidate, the prescription of an adequate tacrolimus dose since the early post-transplant days is considered to be of the utmost importance [36]. Likewise, Hu et al., suggested a positive relation between the time needed to reach a therapeutic tacrolimus trough level and the occurrence of acute rejection. This relation is unique for each recipient and helps explain why in some cases acute rejection occurs despite tacrolimus being within the therapeutic range [37].

The importance of CYP3A5*3 gene polymorphism in affecting the bioavailability of tacrolimus, already suggested by our group [20], is confirmed by the pharmacokinetic data of this study (Tables 5 and 7). Our results also suggest that being a carrier of allele A for CYP3A5 is not the only risk factor to be considered for the prevention of acute rejection, and that other factors may counterbalance its negative effect.

Table 6  Tacrolimus pharmacokinetic data and occurrence of acute rejection (AR) in the 49 patients of the study

| Days     | No AR (41 patients) | AR (8 patients) |
|----------|---------------------|-----------------|
| Dose/kg (mg/kg) |                     |                 |
| day 7    | 0.17 ± 0.08         | 0.13 ± 0.03     |
| day 30   | 0.15 ± 0.08         | 0.15 ± 0.06     |
| day 90   | 0.11 ± 0.08         | 0.11 ± 0.08     |
| day 80   | 0.09 ± 0.07         | 0.10 ± 0.04     |
| day 360  | 0.07 ± 0.06         | 0.08 ± 0.04     |
| CO/(dose/kg) (ng/ml)/(mg/kg) |   |                 |
| day 7    | 78.07 ± 45.55       | 100.51 ± 89.31  |
| day 30   | 115.22 ± 86.70      | 72.48 ± 42.91   |
| day 90   | 115.37 ± 97.21      | 91.56 ± 49.57   |
| day 180  | 130.45 ± 102.76     | 90.36 ± 64.71   |
| day 360  | 190.11 ± 196.61     | 98.31 ± 51.3    |

Data are expressed as mean ± s.d. Mann Whitney was used as statistical test

To explain further, the most interesting result of this study concerns the putative protective role of SXR A7635G homozygous GG polymorphism against acute rejection, which is the first report of a protective polymorphism in the immunology of kidney rejection.

Only a few studies about SXR gene polymorphism and rejection have been published so far. Two articles reported that subjects homozygous GG for SXR A7635G had an increase in the CYP and ABCB1 expression [38, 39] and consequently, a low tacrolimus area under the curve [24–26]. In our study we did not find any positive correlation between the above cited SXR polymorphism and tacrolimus trough level (Table 5).

It can be argued that that the SXR protective effect does not result from an interference of the SXR polymorphism with the metabolism of tacrolimus, but rather from a possible suppression of the rejection mechanism itself, working upstream of the drug metabolic pathway [22, 23]. In fact, SXR makes a heterodymer with the

Table 7  Tacrolimus pharmacokinetic data in relation to CYP3A5 gene polymorphisms in the 8 patients with acute rejection (AR)

| Days     | AA/AG with AR (5 patients) | GG with AR (3 patients) | AA/AG without AR (7 patients) |
|----------|-----------------------------|-------------------------|-----------------------------|
| Dose/kg (mg/kg) |                     |                         |                             |
| day 7    | 0.14 ± 0.01                 | 0.11 ± 0.05             | 0.19 ± 0.14                 |
| day 30   | 0.20 ± 0.03*                | 0.09 ± 0.03             | 0.18 ± 0.13                 |
| day 90   | 0.14 ± 0.05*                | 0.08 ± 0.01             | 0.16 ± 0.12                 |
| day 80   | 0.13 ± 0.04*                | 0.06 ± 0.01             | 0.14 ± 0.10                 |
| day 360  | 0.10 ± 0.04                 | 0.05 ± 0.02             | 0.13 ± 0.10                 |
| CO/(dose/kg) (ng/ml)/(mg/kg) |   |                         |                             |
| day 7    | 55.56 ± 20.87               | 175.42 ± 120.49         | 74.92 ± 62.45               |
| day 30   | 45.81 ± 10.91 *#            | 105.81 ± 47.40          | 92.53 ± 49.62               |
| day 90   | 63.92 ± 26.57*#            | 126.11 ± 54.57          | 110.56 ± 55.25              |
| day 180  | 55.33 ± 23.42*             | 134.14 ± 77.98          | 79.78 ± 35.21               |
| day 360  | 79.48 ± 49.34              | 121.85 ± 50.87          | 66.35 ± 37.25               |

Data are expressed as mean ± s.d. Mann Whitney was used as statistical test
* p-value < 0.05 AA/AG vs GG patients with acute rejections
# p-value < 0.05 AA/Ag with acute rejection vs AA/AG without acute rejection
protein HSP90, a chaperone that is involved in acute rejection, and binds to FKBP5, a protein of the same family of the tacrolimus target protein [40–42]. Consequently, the interaction between SXR and HSP90-FKBP5 may interfere with the acute rejection mechanism.

According to our data, both pre-transplantation genetic screening for SXR A7635G and CYP3A5*3 polymorphisms and post-transplantation drug monitoring could help in preventing an ineffective tacrolimus trough level by identifying the carriers of either protective or risk factors.

A limitation of this study is the relatively low number of patients for each evaluated cohort, in particular of patients GG for SXR A7635G. However, these numbers are similar to those of other pediatric articles on the same topic [43, 44].

Conclusion
In conclusion, this study, along with the other retrospective studies [45, 46], demonstrate the importance of pharmacokinetics and pharmacogenomics to decrease the occurrence of acute rejection, however, there still remain several barriers to their routine clinical application [46]. Pharmacogenomics of tacrolimus can drive the clinical decision regarding the starting dose, with a benefit for the transplanted patients, as it was previously described [46]. Even if pharmacogenetics suffer from some grade of imprecision, due to the interaction of several polymorphisms, in the case of tacrolimus it should be performed together with the classical therapeutic drug monitoring, which is able to reduce the inter-individual pharmacokinetic variability.

In this way, the genetic analysis for CYP3A5*3 and SXR A7635G polymorphisms, performed in advance of transplantation, may be of help in forecasting the risk of acute rejection and in choosing the appropriate tacrolimus dosage for each individual patient in the first year after kidney transplantation.

Abbreviations
SNP: Single nucleotide polymorphism; HLA: Human leucocyte antigen; CYP: Cytochrome P-450; CYP3A5: Cytochrome P-450 3A5; CYP3A5*3: Variant *3 of cytochrome P-450 3A5 rs776746G > A; SXR: Steroid xenobiotic receptor; ABCB 1: ATP Binding Cassette Subfamily B Member 1; HSP90: Heat shock protein 90; FKBP: FK506 binding protein

Acknowledgements
Authors thank Yashika Narang for her contribution about English language.

Authors’ contributions
All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by ST1 and ST2. The first draft of the manuscript was written by ST1 who is also the corresponding author. Manuscript was reviewed and edited by AE, LG and WM. GM critically revised the article and supervision. All authors commented on previous versions of the manuscript. The authors read and approved the final manuscript.

Funding
Not applicable.

Availability of data and materials
The datasets during and/or analysed during the current study available from the corresponding author on reasonable request.

Ethics approval and consent to participate
IRB/Ethics Committee Committee approval. The study was conducted after approval by the ethic committee of IRCCS Ca Granda Ospedale Maggiore Policlinico. Genetic analyses were performed after written parental consent having read the information for the processing of genetic and personal data. Patients were enrolled following the Helsinki declaration.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing and conflict of interests.

Author details
1Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico UOC Nefrologia Dialisi e Trapianto pediatrico, Via della, Commenda 9, 20122 Milan, Italy. 2Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.

Received: 3 February 2020 Accepted: 18 May 2020
Published online: 25 May 2020

References
1. Eldering H, Tedesco-Silva H, Demirabas A, Vitko S, Nashan B, Gurkan A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007;357:2562–75.
2. Filipponi EJ, Farber JL. The implication of B-lineage cells in kidney allografts. Transplantation. 2020. https://doi.org/10.1097/TP.0000000000003163 [Epub ahead of print].
3. Ingulli E. Mechanism of cellular rejection in transplantation. Pediatr Nephrol. 2010;25:61–74.
4. Cole EH, Johnston O, Rose CL, Gill JS. Impact of acute rejection and new-onset diabetes on long-term transplant graft and patient survival. Clin J Am Soc Nephrol. 2008;3:814–21.
5. Dunn TB, Moreen H, Gillingham K, Maurer D, Ozturk O, Pruett TL, et al. Revisiting traditional risk factors for rejection and graft loss after kidney transplantation. Am J Transplant. 2011;11:2132–43.
6. Kuo HAT, Sampaio MS, Vincenti F, Bunnapradist S. Associations of pretransplant diabetes mellitus, new-onset diabetes after transplant, and acute rejection with transplant outcomes: an analysis of the organ procurement and transplant network/united network for organ sharing (OPTN/UNOS) database. Am J Kidney Dis. 2010;55:1127–39.
7. Lebranchu Y, Baan C, Biancone L, Legendsie C, Morales JM, Naesens M, et al. Pretransplant identification of acute rejection risk following kidney transplantation. Transpl Int. 2013;26:129–38.
8. Nichol P, Bestard O, Volk HD, Renke P. Diagnostic value of T-cell monitoring assays in kidney transplantation. Curr Opin Organ Transplant. 2009;14:426–31.
9. Snijder PM, van den Berg E, Whiteman M, Bakker SJ, Leuvenink HG, van Goor H. Emerging role of gasotransmitters in renal transplantation. Am J Transplant. 2013;13:3067–75.
10. Aj M, Smith JM, Skeans MA, Thompson B, Gustafson SK, Schnitzler MA, et al. OPTN/SRTR 2012 annual data report: kidney. Am J Transplant. 2014;15:1211–44.
11. Hesselink DA, van Schaik RH, van der Heiden IP, van der Werf M, Gregoor PJ, Lindemans J, et al. Genetic polymorphism of the CYP3A4, CYP3A5, and MDR1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther. 2003;74:245–54.
12. Chouduri S, Kaassen CD. Structure, function, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCCC (MRP), and ABCG2 (BCRP) efflux transporters. Int J Toxicol. 2006;25:231–59.
13. B-Shir S, Al SHab M, Zayed K, Almady M, Zihlif M. Association between CYP1A2 and CYP3A5 genotype and cyclosporine’s blood levels and dose among Jordanian kidney transplanted patients. Curr Drug Metab. 2019;20:682–94.
14. Leonard GD, Fojo T, Bates TE. The role of ABC transporters in clinical practice. Oncologist. 2003;8:411–21.
15. Kotowski MJ, Bogacz A, Bartkowiak-Wieczorek J, Tejchman K, Dziewanski K, Ostrowski M, et al. Effect of multidrug-resistant (MDR1) and CYP3A4*1B
